JQKD82 是 KDM5 的选择性抑制剂，可增加 H3K4me3。 JQKD82可用于治疗多发性骨髓瘤的研究。

JQKD82 is a selective inhibitor of KDM5 and increases H3K4me3. JQKD82 can be used in studies about the treatment of multiple myeloma.

In MM.1S and MOLP-8 cells, JQKD82 (1 μM) induces G1 cell cycle arrest. JQKD82 (0.3 μM) increases global H3K4me3 levels in MM.1S cells. JQKD82 (0.1-10 μM) inhibits the growth of MM.1S cells in a dose- and time-dependent manner (IC50 = 0.42 μM)[1].

In female NSG mice bearing MOLP-8 TurboGFP-Luc cells, JQKD82 (50 and 75 mg/kg; i.p.) significantly reduces tumor burden. JQKD82 increases the level of H3K4me3 and significantly reduces MYC immuno-staining in vivo[1].

2410512-38-6

C27H40N4O5

500.63

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years